SAPHNELO CONCENTRATE FOR SOLUTION FOR INFUSION 150 MG/ML [SIN17630P]
Active ingredients: ANIFROLUMAB
Product Info
SAPHNELO CONCENTRATE FOR SOLUTION FOR INFUSION 150 MG/ML
[SIN17630P]
Product information
Active Ingredient and Strength | ANIFROLUMAB - 150 MG/ML |
Dosage Form | INFUSION, SOLUTION CONCENTRATE |
Manufacturer and Country | ASTRAZENECA NIJMEGEN B.V. - NETHERLANDS |
Registration Number | SIN17630P |
Licence Holder | ASTRAZENECA SINGAPORE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | L04AG11 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
4.1 Therapeutic indications
SAPHNELO (anifrolumab) is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.
Dosing
4.2 Posology and method of administration
Posology
The recommended dose of SAPHNELO is 300 mg, administered as an intravenous infusion over a 30-minute period, every 4 weeks.
Missed dose
If a planned infusion is missed, administer SAPHNELO as soon as possible. A minimum interval of 14-days should be maintained between doses.
Special populations
Elderly (≥ 65 years old)
No dose adjustment is required. There is limited information in subjects aged ≥ 65 years (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Renal impairment
No dose adjustment is required. No specific studies with SAPHNELO have been conducted in patients with renal impairment. There is no experience in patients with severe renal impairment or end-stage renal disease (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Hepatic impairment
No dose adjustment is required. No specific studies have been conducted in patients with hepatic impairment (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Paediatric population
The safety and efficacy of SAPHNELO in children and adolescents (aged < 18 years old) have not yet been established. No data are available.
Method of administration
SAPHNELO is for intravenous (IV) use.
Following dilution with sodium chloride (0.9%) solution for injection, SAPHNELO is administered as an IV infusion over a 30-minute period. Do not administer as an intravenous push or bolus injection. For instructions on the dilution and storage of the medicinal product before administration, see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
The infusion rate may be slowed or interrupted if the patient develops an infusion reaction.
Contraindications
4.3 Contraindications
None.
